Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study
Authors
Keywords
-
Journal
Molecular Autism
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-07
DOI
10.1186/s13229-020-00335-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Off-Label Use of Bumetanide for Brain Disorders: An Overview
- (2019) Shivani C. Kharod et al. Frontiers in Neuroscience
- A randomized controlled trial with everolimus for IQ and autism in tuberous sclerosis complex
- (2019) Iris E. Overwater et al. NEUROLOGY
- Chloride transporters and GABA polarity in developmental, neurological and psychiatric conditions
- (2018) Joran T. Schulte et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Measuring Health-Related Quality of Life in Tuberous Sclerosis Complex – Psychometric Evaluation of Three Instruments in Individuals With Refractory Epilepsy
- (2018) Petrus J. de Vries et al. Frontiers in Pharmacology
- Effect of Mexiletine on Muscle Stiffness in Patients With Nondystrophic Myotonia Evaluated Using Aggregated N-of-1 Trials
- (2018) Bas C. Stunnenberg et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- TuberOus SClerosis registry to increase disease Awareness (TOSCA) – baseline data on 2093 patients
- (2017) John C. Kingswood et al. Orphanet Journal of Rare Diseases
- NKCC1 Chloride Importer Antagonists Attenuate Many Neurological and Psychiatric Disorders
- (2017) Yehezkel Ben-Ari TRENDS IN NEUROSCIENCES
- Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders
- (2017) E Lemonnier et al. Translational Psychiatry
- Everolimus for treatment of tuberous sclerosis complex-associated neuropsychiatric disorders
- (2017) Darcy A. Krueger et al. Annals of Clinical and Translational Neurology
- Functional aspects of early brain development are preserved in tuberous sclerosis complex (TSC) epileptogenic lesions
- (2016) Gabriele Ruffolo et al. NEUROBIOLOGY OF DISEASE
- The use of everolimus in the treatment of neurocognitive problems in tuberous sclerosis (TRON): study protocol for a randomised controlled trial
- (2016) Elizabeth Randell et al. Trials
- Normal P50 Gating in Children with Autism, Yet Attenuated P50 Amplitude in the Asperger Subcategory
- (2015) Gitte Falcher Madsen et al. Autism Research
- Neurological and neuropsychiatric aspects of tuberous sclerosis complex
- (2015) Paolo Curatolo et al. LANCET NEUROLOGY
- Tuberous Sclerosis Associated Neuropsychiatric Disorders (TAND) and the TAND Checklist
- (2015) Petrus J. de Vries et al. PEDIATRIC NEUROLOGY
- The mismatch negativity (MMN) potential as a tool for the functional mapping of temporal lobe epilepsies
- (2014) Ricardo Lopes et al. EPILEPSY & BEHAVIOR
- Selective suppression of excessive GluN2C expression rescues early epilepsy in a tuberous sclerosis murine model
- (2014) N. Lozovaya et al. Nature Communications
- Increased Prepulse Inhibition and Sensitization of the Startle Reflex in Autistic Children
- (2013) Gitte Falcher Madsen et al. Autism Research
- Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference
- (2013) Darcy A. Krueger et al. PEDIATRIC NEUROLOGY
- Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference
- (2013) Hope Northrup et al. PEDIATRIC NEUROLOGY
- Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy
- (2012) Sanaz Eftekhari et al. EPILEPSIA
- Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments
- (2012) Wolfgang Löscher et al. NEUROPHARMACOLOGY
- A randomised controlled trial of bumetanide in the treatment of autism in children
- (2012) E Lemonnier et al. Translational Psychiatry
- Altered inhibition in tuberous sclerosis and type IIb cortical dysplasia
- (2011) Delia M. Talos et al. ANNALS OF NEUROLOGY
- Abnormal mismatch negativity for pure-tone sounds in temporal lobe epilepsy
- (2011) Miho Miyajima et al. EPILEPSY RESEARCH
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
- (2011) M. Herdman et al. QUALITY OF LIFE RESEARCH
- The diuretic bumetanide decreases autistic behaviour in five infants treated during 3 months with no side effects
- (2010) Eric Lemonnier et al. ACTA PAEDIATRICA
- Targeted treatments for cognitive and neurodevelopmental disorders in tuberous sclerosis complex
- (2010) Petrus J. Vries Neurotherapeutics
- Development of the EQ-5D-Y: a child-friendly version of the EQ-5D
- (2010) Nora Wille et al. QUALITY OF LIFE RESEARCH
- The natural history of epilepsy in tuberous sclerosis complex
- (2009) Catherine J. Chu-Shore et al. EPILEPSIA
- Decreased Seizure Activity in a Human Neonate Treated With Bumetanide, an Inhibitor of the Na+-K+-2Cl- Cotransporter NKCC1
- (2009) Kristopher T. Kahle et al. JOURNAL OF CHILD NEUROLOGY
- Tuberous sclerosis
- (2008) Paolo Curatolo et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started